All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

11

2023 to 2026

Breakthrough

5

Accelerated

5

Priority review

8

Orphan

9

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202300
202434
202510
202630

11 approvals

Newest first. Hover a badge for what it means.

  • Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
    Original approval · NDA 220425NovelPriority reviewOrphanApproval letter

    To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

  • Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
    Original approval · NDA 220910NovelPriority reviewOrphanApproval letter

    To treat metastatic pancreatic cancer

  • Lynavoy (Linerixibat) · InterceptMar 17, 2026
    Original approval · NDA 220295NovelOrphanApproval letter

    To treat cholestatic pruritus associated with primary biliary cholangitis

  • Nereus (Tradipitant) · Vanda Pharms INCDec 30, 2025
    Original approval · NDA 220152NovelApproval letter

    To treat vomiting associated with motion

  • Bizengri (Zenocutuzumab-Zbco) · Merus N.V.Dec 4, 2024
    Original approval · BLA 761352NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat non-small cell lung cancer and pancreatic adenocarcinoma

  • Ziihera (Zanidatamab-Hrii) · Jazz PharmsNov 20, 2024
    Original approval · BLA 761416NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer

  • Vyloy (Zolbetuximab-Clzb) · AstellasOct 18, 2024
    Original approval · BLA 761365NovelPriority reviewOrphanApproval letter

    To treat gastric or gastroesophageal junction adenocarcinoma

  • Livdelzi (Seladelpar Lysine) · Gilead Sciences INCAug 14, 2024
    Original approval · NDA 217899NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat primary biliary cholangitis (PBC)

  • Iqirvo (Elafibranor) · IpsenJun 10, 2024
    Original approval · NDA 218860NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat primary biliary cholangitis in combination with ursodeoxycholic acid

  • Rezdiffra (Resmetirom) · MadrigalMar 14, 2024
    Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring

  • Tevimbra (Tislelizumab-Jsgr) · BeigeneMar 13, 2024
    Original approval · BLA 761232NovelOrphanApproval letter

    To treat unresectable or metastatic esophageal squamous cell carcinoma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.